Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Intelligent Bio SolutionsINBS -7.36%49 Debt-to-Equity is 0.21 as of Mar. 2026, which is 110% above its 10-year median of 0.10. GuruFocus rates INBS with a GF Score™ of 49/100 and a GF Value™ of $2.71 (Fairly Valued). The stock has 3 warning signs investors should review. Among 703 Medical Devices & Instruments companies, Intelligent Bio Solutions ranks better than 52.2% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Intelligent Bio Solutions's Debt-to-Equity or its related term are showing as below:
INBS'
s Debt-to-Equity Range Over the Past 10 Years
Min: -1.7 Med: 0.1 Max: 0.86
Current: 0.21
During the past 9 years, the highest Debt-to-Equity Ratio of Intelligent Bio Solutions was 0.86. The lowest was -1.70. And the median was 0.10.
INBS's Debt-to-Equity is ranked better than 52.2% of 703
companies
in the Medical Devices & Instruments industry
Industry Median: 0.23
vs INBS: 0.21
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Intelligent Bio Solutions Debt-to-Equity Related Terms
Intelligent Bio Solutions Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
INBS vs RMSL, USAQ, ITOC: Debt-to-Equity Comparison
For the Medical Devices subindustry, Intelligent Bio Solutions's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Intelligent Bio Solutions Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Intelligent Bio Solutions's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Intelligent Bio Solutions's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Intelligent Bio Solutions (INBS) has a Debt-to-Equity of 0.21 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Intelligent Bio Solutions and its competitors. This is 110% above median its historical median of 0.10. According to the industry distribution chart, Intelligent Bio Solutions ranks #336 out of 703 companies in the Medical Devices & Instruments industry, placing it in the top 47.8%.
Is Intelligent Bio Solutions' Debt-to-Equity too high?
Intelligent Bio Solutions' current Debt-to-Equity of 0.21 is 110% above median its 10-year median of 0.10. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. Intelligent Bio Solutions' value of 0.21 is 8.7% below this industry median. Based on the distribution chart, Intelligent Bio Solutions ranks #336 out of 703 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Intelligent Bio Solutions has a GF Score™ of 49/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Intelligent Bio Solutions' Debt-to-Equity compare to RMSL and USAQ?
According to the Medical Devices & Instruments industry distribution chart, Intelligent Bio Solutions ranks #336 out of 703 companies for Debt-to-Equity. This puts Intelligent Bio Solutions in the upper half of its industry. The industry median Debt-to-Equity is 0.23. Intelligent Bio Solutions' value of 0.21 is 8.7% below this benchmark. While the company's 10-year median is 0.10 vs. the industry median of 0.23, Intelligent Bio Solutions has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 703 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Intelligent Bio Solutions's current Debt-to-Equity of 0.21 is 8.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Intelligent Bio Solutions and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Intelligent Bio Solutions's current Debt-to-Equity is 0.21, which is 110% above median its own 10-year median of 0.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intelligent Bio Solutions stock overvalued right now?
Based on GuruFocus' analysis, Intelligent Bio Solutions (INBS) is currently considered Fairly Valued. The stock's GF Value™ is $2.71, compared to a current price of $2.77 — trading 2.2% above its estimated fair value. The current Debt-to-Equity is 0.21, which is 110% above median its 10-year median of 0.10 and 8.7% below the Medical Devices & Instruments industry median of 0.23. Intelligent Bio Solutions' overall GF Score™ is 49/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Intelligent Bio Solutions (INBS), the current Debt-to-Equity is 0.21 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Intelligent Bio Solutions (INBS) Overvalued in 2026?
Based on GuruFocus' analysis, Intelligent Bio Solutions stock appears to be overvalued.
The current stock price of $2.77 is trading 2.2% above its estimated GF Value™ of $2.71.
GuruFocus considers Intelligent Bio Solutions to be Fairly Valued.
Key valuation signals for INBS:
Debt-to-Equity: 0.21 (110% above median its 10-year median of 0.10)
GF Value™: $2.71 vs. price of $2.77 (2.2% above fair value)
Industry Position: 8.7% below the Medical Devices & Instruments median (#336 of 703)
No single metric tells the full story. See the INBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company operates through new reportable segments: United Kingdom; Asia Pacific (APAC); Americas; and Rest of World, of which United Kingdom derives maximum revenue.
49GF Score
Get the complete analysis for INBS
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INBS has been successfully added to your 
